Cost-effectiveness Analysis of Risperidone and Quetiapine in the Treatment of Schizophrenia
- VernacularTitle:利培酮与奎硫平治疗精神分裂症的成本-效果分析
- Author:
Jianqing TAO
;
Jie SHI
;
Hong KANG
;
Jia LIANG
;
Ming YE
;
Lan ZHU
;
Qiang ZENG
- Publication Type:Journal Article
- Keywords:
Risperidone;
Quetiapine;
Cost-effectiveness analysis
- From:
China Pharmacy
2001;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the econamics effect of risperidone and quetiapine in treating of schizophrenia.METH ODS:64schizophrenia patients were randomly divided into risperidone group(34cases)and quetiapine group(30cases).The effects were evaluated based on the reduction of scores determined by brief psychiatric rating scale(BPRS);the adverse effects were evaluated by treatment emergent symptom scale(TESS).And then the cost-effectiveness analysis was carried through.RESULTS:The per capita costs for risperidone and quetiapine were3598.85yuan and3778.63yuan respectively;the re-duction of BPRS scores were(36.09?15.52)and(25.03?14.45)respectvely;the respective cost-effect ratio was99.72yuan and150.96yuan;the increment of the cost-effect ratio for the quetiapine group was-16.25compared with the risperidone group.CONCLUSION:Risperidone is more economical than quetiapine in the treatment of schizophrenia.
